How should DSIP be stored and reconstituted?

Lyophilised DSIP stores at −20°C for 18–24 months. After reconstitution with bacteriostatic water, the solution holds at 4°C for 14–28 days. Avoid freeze-thaw cycles of reconstituted material. Travel with cold packs in insulated containers; avoid prolonged exposure above 25°C. The standard reconstitution concentration is 1–2 mg/mL depending on the vial size.

What class of compound is DSIP?

DSIP is classified as a Neuropeptide (sleep). Within this class, alternative names and analogues include Delta Sleep-Inducing Peptide. The class-level pharmacology shapes both the clinical applications and the safety profile; the body composition / training literature treats DSIP alongside its class peers when evaluating relative merits.

Is DSIP safe during pregnancy or breastfeeding?

DSIP, like most non-approved peptide therapeutics, does not have safety data supporting use during pregnancy or lactation. The default position is contraindication during pregnancy, lactation, and active conception, with discontinuation at least 2–3 cycles before planned conception. Approved indications (where they exist) may have specific guidance — verify with the prescribing physician.

What are the safety considerations for DSIP?

Excellent safety record across decades of research use. No reported serious adverse events. Avoid combining with strong CNS depressants. For anabolic and recovery use, additional considerations: baseline labs appropriate to the targeted system, mid-cycle re-check at 4–6 weeks, and end-of-cycle full re-evaluation. DSIP's ~7 min plasma; CNS effects longer pharmacokinetic profile and subq/intranasal administration route influence the side-effect profile in predictable ways.

Will DSIP actually increase lean mass?

DSIP's effect on body composition depends on which dimension of the anabolic cascade it engages. Direct anabolic pathway engagement is not the principal mechanism, but contributions to recovery, connective tissue, and inflammatory tone produce measurable body-composition shifts in trained users. Effect size is proportional to training stimulus and nutritional adequacy.

Home/ Compounds/ DSIP

DSIP

Body Composition

Athletes and performance coaches evaluating DSIP for body composition focus on three measurable endpoints: lean mass, recovery capacity, and the rate of return to training intensity between sessions. Mechanism remains incompletely characterised Effects observed on delta-wave (slow-wave) sleep promotion, opioid receptor modulation indirectly via μ-receptor systems, and HPA axis dampening. Crosses the blood-brain barrier.. The 100-500 mcg 1x daily before sleep protocol over the standard 8-12 week cycle, paired with training stimulus and nutritional adequacy, is where the body-composition response is generated.

Body Composition / Training Applications

Fat LossTraining PerformanceMuscle EnduranceStrengthWorkout Recovery

Key Takeaways

Body composition lens: response to DSIP is proportional to training stimulus and nutritional adequacy.
Mechanism: Mechanism remains incompletely characterised.
Body composition dose: 100-500 mcg 1x daily before sleep via subq/intranasal; effects visible at week 4-8 with adequate training and protein.
Cycle structure: 8-12 weeks on, 4 weeks off; training-day or daily dosing depending on half-life.
Performance stack partners: IGF-1 LR3, CJC-1295 + Ipamorelin Blend, TB-500.

Body Composition / Training Mechanism

Mechanism remains incompletely characterised. Effects observed on delta-wave (slow-wave) sleep promotion, opioid receptor modulation indirectly via μ-receptor systems, and HPA axis dampening. Crosses the blood-brain barrier. The body composition layer follows: how the compound contributes to anabolic substrate, how it shapes the recovery window between training sessions, how training-day dosing differs from rest-day dosing, and which structural-adaptation dimension (hyperplasia or hypertrophy) is most affected by DSIP.

Anabolic substrate and protein synthesis

DSIP's relevance to body composition depends on where in the anabolic cascade it acts. It acts on adjacent rather than directly anabolic pathways, but the contribution to recovery, connective tissue, and inflammatory tone produces measurable body-composition effects in trained users. The downstream effect on body composition is dose- and training-dependent.

Hyperplasia and structural adaptation

Where DSIP demonstrates effects on fibre count rather than fibre size — hyperplasia rather than hypertrophy — the structural adaptation matters more than the acute anabolic signal. Most peptides in this category contribute to the hypertrophic rather than hyperplastic adaptation, with the magnitude depending on training stimulus.

Training-day versus rest-day dosing

Many peptides in this category respond better to training-day-only versus rest-day-included dosing. DSIP with a ~7 min plasma; CNS effects longer half-life of ~7 min plasma; CNS effects longer is short-lived enough that timing relative to training sessions matters. The practical dosing schedule reflects this.

Body Composition / Training Applications

Fat Loss

Fat Loss responds to DSIP with effect sizes proportional to training stimulus and nutritional adequacy. Users running aggressive caloric deficits see reduced response; users in surplus with adequate protein see proportionally larger response. Programming the inputs is half the protocol.

Training Performance

For training performance, DSIP integrates with training programming on a per-session and per-cycle basis. Training-day dosing produces stronger acute effect; rest-day inclusion supports sustained baseline. The protocol pattern reflects training intensity and recovery demand.

Lean Mass

The body composition community converges on DSIP for lean mass with reported best-fit cycles of 8–12 weeks. Off-cycle of 4 weeks is standard. Stacking with complementary peptides on different pathways is the typical pattern for advanced users.

Tendon Repair

Tendon Repair responds to DSIP with effect sizes proportional to training stimulus and nutritional adequacy. Users running aggressive caloric deficits see reduced response; users in surplus with adequate protein see proportionally larger response. Programming the inputs is half the protocol.

Dosing Protocol

Goal	Route	Dose	Cycle
Standard protocol	SubQ	100-500 mcg	8–12 weeks on / 4 weeks off
Conservative starter	SubQ	60-500 mcg	4–6 weeks initial cycle
Body Composition focus	SubQ	100-500 mcg	1x daily before sleep
Maintenance phase	SubQ	70-500 mcg	Ongoing with periodic pauses

Dose timing for DSIP is important relative to food and training given the short half-life. Consistency through the cycle is more important than the precise clock time of individual doses.

Stacking

DSIP stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from performance coaches and athletes.

DSIP + IGF-1 LR3: Binds the IGF-1 receptor with full agonist activity. Pairs naturally with DSIP's mechanism in body composition / training protocols.
DSIP + CJC-1295 + Ipamorelin Blend: CJC-1295 stimulates the GHRH receptor; ipamorelin stimulates the ghrelin/GHSR receptor. Pairs naturally with DSIP's mechanism in body composition / training protocols.
DSIP + TB-500: Binds G-actin monomers and prevents their incorporation into F-actin filaments, regulating the cellular actin pool. Pairs naturally with DSIP's mechanism in body composition / training protocols.
DSIP + BPC-157: Upregulates VEGFR2 to promote angiogenesis and activates the FAK-paxillin pathway for accelerated tissue repair. Pairs naturally with DSIP's mechanism in body composition / training protocols.

Safety & Regulatory Status

WADA: Not on prohibited list FDA: Unapproved Research: Preclinical + small human series

Excellent safety record across decades of research use. No reported serious adverse events. Avoid combining with strong CNS depressants.

Lens-specific safety considerations for body composition / training use of DSIP: Excellent safety record across decades of research use. No reported serious adverse events. Avoid combining with strong CNS depressants. Additional body composition / training monitoring at baseline and 6–8 week follow-up is appropriate.

Clinical Evidence

Primary

DSIP — characterisation and effects on sleep

PMID 6324019

Supporting

DSIP and HPA axis modulation

PMID 20066503

DSIP vs Related Peptides

Compound	Profile	Onset	Best For
DSIP	Neuropeptide (sleep)	~7 min plasma; CNS effects longer	Body Composition
IGF-1 LR3	Modified insulin-like growth factor 1	~20-30 hr (vs ~10 min for native IGF-1)	A modified IGF-1 with a 13-amino-acid N-terminal extension and Arg substitution that resists IGFBP binding — extending half-life from 10 minutes to roughly a day
Tesamorelin	Stabilised GHRH analogue	~30 min	An FDA-approved long-chain GHRH analogue used for HIV-associated lipodystrophy and notable for its consistent effect on visceral adipose reduction
Ipamorelin	Selective GHRP / ghrelin mimetic	~2 hr	The most selective ghrelin-receptor agonist among the GHRPs — stimulates GH release with minimal effect on cortisol, prolactin, or appetite

Frequently Asked Questions

Effect timeline for body composition?

Acute pump and recovery effects within 1–2 weeks. Visible body composition shifts at 4–8 weeks for trained users with adequate nutrition. Peak effect at the end of a 12-week cycle; partial regression during the 4-week off-period. Total trajectory is incremental rather than dramatic.

Best stack pairing for lean mass?

The canonical lean mass stack pairs DSIP with a complementary GH-axis component, a connective-tissue support peptide, and — in advanced protocols — an anabolic-supportive component. Specific pairings depend on which dimension of body composition is prioritised: pure mass, mass-and-fat-loss, or recovery-focused.

How does DSIP compare to AAS for body composition?

Peptide therapeutics including DSIP produce more modest body composition shifts than anabolic-androgenic steroids and operate on different mechanisms with substantially different side-effect profiles. The compound is most-appropriate for users prioritising long-term sustainability and clean blood work over maximum acute mass.

Will DSIP affect my training performance?

Most commonly via faster recovery between sessions, which permits higher training frequency and intensity. Acute performance-enhancing effects in a single session are not the typical profile. Users typically need to upregulate nutrition and adjust programming to take advantage of the increased recovery capacity.

What is the mechanism of action of DSIP?

Mechanism remains incompletely characterised. Effects observed on delta-wave (slow-wave) sleep promotion, opioid receptor modulation indirectly via μ-receptor systems, and HPA axis dampening. Crosses the blood-brain barrier. For anabolic and recovery applications specifically, the relevant downstream consequence is the cascade from receptor engagement to systemic effect: Mechanism remains incompletely characterised. The body composition / training interpretation focuses on the pathway-level detail rather than on any single high-level summary.

What should I look for in DSIP sourcing and quality?

Acceptable DSIP certificates of analysis specify: lot-specific (not template) issuance, HPLC purity ≥98%, mass spec confirmation matching 848 Da, endotoxin testing for injectable routes, and third-party accredited laboratory issuance. Template COAs, missing endotoxin data, or vendor-internal labs are red flags. Pharmaceutical-grade compounded material is the lowest-risk supply path where accessible.

Clinical Protocol

Start a DSIP Protocol

Alukard provides physician-supervised body composition protocols with GMP-certified DSIP and GMP-certified compounds and training-aware dosing guidance.

Get Protocol

Quick Facts

Molecular weight: 848 Da
Sequence length: 9 aa
Half-life: ~7 min plasma; CNS effects longer
WADA: Not on prohibited list
FDA: Unapproved
Research: Preclinical + small human series

Stack Partners

IGF-1 LR3

CJC-1295 + Ipamorelin Blend

TB-500

BPC-157

Tesamorelin + Ipamorelin Blend

Research Note

All body composition / training applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for DSIP unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.

Physician-supervised body composition protocols

Start Your Body Composition / Training Protocol for DSIP

Alukard provides physician-supervised body composition protocols with GMP-certified compounds and training-aware dosing guidance.

Get a Physician Consultation View All Compounds

HIPAA Compliant · GMP Certified · Physician Supervised